| Market Cap | 36.49M | P/E | - | EPS this Y | 18.70% | Ern Qtrly Grth | - |
| Income | -97.76M | Forward P/E | -0.56 | EPS next Y | 57.80% | 50D Avg Chg | -10.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -23.00% |
| Dividend | N/A | Price/Book | 0.60 | EPS next 5Y | - | 52W High Chg | -67.00% |
| Recommedations | 2.00 | Quick Ratio | 1.41 | Shares Outstanding | 38.44M | 52W Low Chg | 23.00% |
| Insider Own | 2.68% | ROA | -51.20% | Shares Float | 27.54M | Beta | 1.09 |
| Inst Own | 24.41% | ROE | -182.70% | Shares Shorted/Prior | 272.73K/3.91M | Price | 0.93 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 119,930 | Target Price | 5.50 |
| Oper. Margin | - | Earnings Date | Apr 29 | Volume | 147,016 | Change | -4.20% |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
| Wedbush | Neutral | Aug 14, 23 |
| Stifel | Hold | Aug 11, 23 |
| HC Wainwright & Co. | Neutral | Aug 11, 23 |
| HC Wainwright & Co. | Buy | Jun 5, 23 |
| Stifel | Buy | May 11, 23 |
| HC Wainwright & Co. | Buy | May 11, 23 |
| Wedbush | Outperform | Mar 30, 23 |
| EF Hutton | Buy | Mar 30, 23 |
| HC Wainwright & Co. | Buy | Mar 30, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Other Other | Oct 19 | Sell | 0.4 | 274,739 | 109,896 | 2,971,128 | 10/23/23 |
| Serafini Tito | Chief Strategy Offic.. Chief Strategy Officer | Aug 02 | Sell | 0.9522 | 5,487 | 5,225 | 72,817 | 08/04/23 |
| CROSS HERB | Chief Financial Offi.. Chief Financial Officer | Aug 02 | Sell | 0.9522 | 5,487 | 5,225 | 72,817 | 08/04/23 |
| Gould Stephen E | Chief Scientific Off.. Chief Scientific Officer | Aug 02 | Sell | 0.9522 | 4,076 | 3,881 | 28,424 | 08/04/23 |
| Courtney Phillips | General Counsel & Se.. General Counsel & Secretary | Aug 02 | Sell | 0.9522 | 4,076 | 3,881 | 57,492 | 08/04/23 |
| Serafini Tito | Chief Strategy Offic.. Chief Strategy Officer | Sep 02 | Sell | 1.7752 | 7,646 | 13,573 | 34,554 | 09/20/22 |
| Orwin John A | President & CEO President & CEO | Sep 02 | Sell | 1.7752 | 20,908 | 37,116 | 100,492 | 09/20/22 |
| CROSS HERB | Chief Financial Offi.. Chief Financial Officer | Sep 02 | Sell | 1.7752 | 7,646 | 13,573 | 34,554 | 09/20/22 |
| Courtney Phillips | General Counsel & Se.. General Counsel & Secretary | Sep 02 | Sell | 1.7752 | 6,432 | 11,418 | 29,068 | 09/20/22 |
| Serafini Tito | Chief Strategy Offic.. Chief Strategy Officer | Jun 28 | Sell | 2.0177 | 15,000 | 30,266 | 228,875 | 06/30/22 |
| Serafini Tito | Chief Strategy Offic.. Chief Strategy Officer | Mar 04 | Sell | 5.00 | 30,000 | 150,000 | 243,875 | 03/08/22 |